Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.

Abstract

OBJECTIVE:

To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Behçet disease (BD).

METHODS:

Thirty-two patients (22 women) with BD received 60 courses of alemtuzumab between 1994 and 2013. Three-dose regimens were used: 134 mg in 21 courses (Group 1), 95 mg in 18 courses (Group 2), and 60 mg in 21 courses (Group 3). Immunosuppressive drugs were stopped at the time of alemtuzumab, and prednisolone was reduced according to clinical response. Treatment response was assessed by clinical status, inflammatory activity, prednisolone dose, and the need for subsequent immunosuppressive drugs and disease relapse.

RESULTS:

After the first alemtuzumab course, 27 of 32 patients (84%) achieved partial or complete remission (CR). Fifty of 60 courses (83%) resulted in remission (66% CR) without differences in remission rates between dosing regimens. Profound lymphocyte depletion occurred after all courses. Relapse-free survival rates were 83.6% at 6 months and 52.8% at 12 months, and were higher among Group 1 patients (Group 1: 100% and 77.8%, Group 2: 81.3% and 37.5%, and Group 3: 65.0% and 37.1%, p < 0.001). Mild to moderate infusion reactions occurred after 16 courses (27%). Eight patients (25%) developed symptomatic thyroid disease.

CONCLUSION:

Alemtuzumab led to remission in the majority of patients with difficult-to-treat BD. Relapse was common and may be associated with lower dosing. Adverse events included infusion reactions and new autoimmunity. Achieving complete lymphocyte depletion did not affect the remission rate or duration.

• Authors: Aladdin J Mohammad, Rona M Smith, Yok W Chow, Afzal N Chaudhry, David R W Jayne
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 42 Issue 10 Pg. 1906-13 (Oct 2015) ISSN: 0315-162X [Print] Canada
• PMID: 26276966 (Publication Type: Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Humanized
• Alemtuzumab

Topics

• Adult
• Alemtuzumab
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Behcet Syndrome (diagnosis, drug therapy, mortality)
• Cohort Studies
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Infusions, Intravenous
• Kaplan-Meier Estimate
• Male
• Remission Induction (methods)
• Retrospective Studies
• Risk Assessment
• Severity of Illness Index
• Statistics, Nonparametric
• Survival Rate
• Time Factors
• Treatment Outcome
• United Kingdom